Her2-positive　breast　cancer　accounts　for　20-25%　of　the　breast　cancer　population　with　lower　survival　rate　and　higher　recurrence　risk　than　non-Her2-positive　breast　cancer.　The　recent　approval　of　trastuzumab　emtansine　(T-DM1),　an　antibody-drug　conjugate,　significantly　improves　therapeutic　outcomes　of　Her2-positve　breast　cancer.　In　this　report,　we　designed　and　fabricated　a　novel　nanodrug　taking　advantage　of　T-DM1　and　mesoporous　silica　coated　gold　nanorods　(GNR@mSiO(2))　to　integrate　multiple　functions　of　active　targeting,　antibody　therapy,　drug　therapy　and　photothermal　therapy　(PTT)　within　one　single　platform　to　fight　against　Her2-positive　breast　cancer.　The　engineered　nanodrug　(GNR@mSiO(2)-TDM1)　has　accelerated　cell　surface　binding　and　internalization　compared　to　the　intact　drug　T-DM1,　which　allows　fast　action　of　the　drug.　GNR@mSiO(2)-TDM1　specifically　ablated　Her2-positive　breast　cancer　cells　in　vitro　through　multi-modal　treatment　with　enhanced　efficiency.　In　addition,　the　engineered　nanodrug　has　amplified　photoacoustic　performance　allowing　sensitive　detection　of　Her2-positive　cancer　cells.　This　represents　a　significant　finding　since,　up　to　now,　only　reduced　graphene　oxide　and　silica　have　been　found　to　enhance　the　photoacoustic　performance　of　gold　nanorods.　These　findings　have　clinical　implications　to　deal　with　the　troubling　issues　of　current　cancer　therapy.　Targeted　multi-modal　ablation　of　breast　cancer　cells　would　greatly　facilitate　the　treatment　safety　and　efficiency,　and　would　be　of　particular　value　in　the　emerging　era　of　personalized　medicine.